Kosan 2004.

Methods	RCT. Parallel design. Location: Turkey. Single centre.
Participants	39 pediatric outpatients with the diagnosis of FMF, diagnosed based on Tel Hashomer criteria. 20 participants randomised to colchicine 2 or 3 times per day (divided‐dose group) and 19 to colchicine once daily (single‐dose group). Age, mean (SD): single‐dose group 9.8 (4.3) years; divided‐dose group 10.2 (4.0) years. Gender: 21 females, 18 males.
Interventions	Single‐dose group: colchicine 0.97 ± 0.35 mg/day once daily. Divided‐dose group: colchicine 0.95 ± 0.30 mg/day, dose divided into 2 or 3 times daily. NB not stated if mean and SD or mean and SE reported.
Outcomes	Number of attacks in the study period. Acute phase response, including: ESR, CRP, fibrinogen, WBC, platelets and ferritin concentration. Adverse events. Outcomes measured at 8 months.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "Patients were randomly divided in two groups", however, the exactly randomization method was unclear.
Allocation concealment (selection bias)	Unclear risk	The exact method of allocation concealment was unclear.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	No blinding, however, the review's secondary outcome of acute phase response was not influenced by lack of blinding.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	No blinding, however, the review's secondary outcome of acute phase response was not influenced by lack of blinding.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No incomplete outcome data reported.
Selective reporting (reporting bias)	Unclear risk	Protocol could not be reviewed; moreover, the methods section did not predefine outcome measurements.
Other bias	High risk	Differences of FMF severity between groups were not described.